Reproductive · PANCE / PANRE

Fibrocystic Breast Changes

Benign cyclic breast lumpiness and tenderness — extremely common; reassurance after exclusion of malignancy.

Also known as: fibrocystic breast disease, fibrocystic changes, breast cysts, benign breast disease

Overview

Constellation of benign, hormonally responsive changes in the breast — stromal fibrosis, cyst formation, ductal hyperplasia, and apocrine metaplasia — producing nodularity and cyclic discomfort. No longer considered a 'disease.'

Epidemiology

Most common benign breast condition; affects ~50-60% of reproductive-age women. Peak incidence ages 30-50. Usually subsides after menopause unless on hormone therapy.

🔒 Free preview limit reached

Keep reading — start your free trial

You've read your 2 free diagnosis previews. Create your free account to unlock the full Fibrocystic Breast Changes outline — plus all 514 diagnoses, 3,500+ board-style questions, flashcards, and an AI tutor. Your 7-day free trial includes everything, and there's no credit card required.

Start your 7-day free trial → Sign in

Free to start · No credit card · Cancel anytime

Risk factors

Age 30-50 (reproductive years)
Estrogen-progesterone imbalance
Hormone therapy
Caffeine and methylxanthine intake (controversial)
Family history

Pathophysiology

Exaggerated cyclic response to ovarian estrogen and progesterone produces stromal proliferation, lobular hyperplasia, and accumulation of fluid in obstructed terminal ductal lobular units → microcyst and macrocyst formation. Most lesions confer no increased cancer risk; atypical hyperplasia (atypical ductal or lobular hyperplasia) does (~4-5x).

Clinical presentation

Symptoms

Bilateral diffuse breast lumpiness, often most prominent in upper outer quadrants
Cyclic breast pain (mastalgia) worse premenstrually, relieved with menses
Palpable cysts that may fluctuate in size with cycle
Generally NOT associated with bloody nipple discharge

Signs / physical exam

Diffuse nodularity, 'cobblestone' texture
Tender areas, especially premenstrually
Discrete cysts may be palpable
No skin or nipple changes; no lymphadenopathy

Differential diagnosis

Breast cancer — Persistent, fixed, irregular mass with skin/nipple changes; imaging and biopsy
Fibroadenoma — Discrete mobile rubbery mass in younger women; well-circumscribed on ultrasound
Simple cyst — Round, anechoic on ultrasound; can aspirate
Mastitis / abscess — Warm, erythematous, tender; fever; lactation or recent skin breach
Phyllodes tumor — Rapidly growing firm mass; benign-to-malignant spectrum
Fat necrosis — Trauma or surgery history

Diagnostic workup

Imaging

Clinical breast exam at multiple cycle points to distinguish cyclic changes from persistent mass
Ultrasound — first-line for women <30 or pregnant; characterizes cysts (anechoic, posterior enhancement)
Mammography — for women ≥30 with palpable mass
Cyst aspiration if symptomatic, complex, or BI-RADS 4: clear/yellow/green/brown fluid → discard; bloody fluid → send for cytology and biopsy wall
Core needle biopsy for solid lesions or recurrent/complex cysts

Diagnostic algorithm

Feature	Fibrocystic Changes	Fibroadenoma	Breast Cyst	Breast Cancer
Age	30-50	15-35	35-50	>40 (usually)
Number / laterality	Multiple, bilateral	Single (sometimes multiple)	Single or multiple	Usually single
Texture	Lumpy, nodular	Firm, rubbery, mobile	Smooth, fluctuant	Hard, fixed, irregular
Cyclic change	Yes (tender premenstrually)	Minimal	Mild	No
Imaging	Heterogeneous, cysts	Well-circumscribed solid	Anechoic, posterior enhancement	Spiculated mass, calcifications
Management	Reassurance, supportive	Observation or excision	Aspiration if symptomatic	Biopsy → oncologic treatment

Distinguishing benign and malignant breast findings.

Treatment

First-line

Reassurance after exclusion of malignancy
Supportive measures: well-fitted supportive bra, warm/cool compresses
NSAIDs (oral or topical diclofenac) for mastalgia
Reduction in caffeine, dietary fat (modest, inconsistent evidence)

Second-line / adjunct

Combined OCP — reduces cyclical pain in some patients
Tamoxifen 10 mg/day or danazol — refractory severe mastalgia; off-label, significant side effects
Evening primrose oil — modest evidence, low risk
Cyst aspiration for symptomatic relief

Complications

Patient anxiety from frequent self-detected lumps
Recurrent cyst formation
Coexistence with malignancy (changes do not protect against cancer)
Atypical hyperplasia subset confers increased breast cancer risk (~4x)

PANCE pearls

Fibrocystic changes themselves do NOT increase breast cancer risk unless histology reveals proliferative changes with atypia.
Cyst aspiration is both diagnostic and therapeutic — clear fluid that does not recur requires no further workup.
Bloody fluid from a cyst, residual mass after aspiration, or rapid recurrence → biopsy.
Cyclic mastalgia is much more common than continuous mastalgia; the latter warrants more thorough evaluation.
Reassure patients that lumpiness varies with cycle — best to re-examine in days 5-10 of cycle when changes are minimal.

References

ACOG CO 821 — ACOG Committee Opinion 821: Benign Breast Conditions and Management
ASBrS 2019 — American Society of Breast Surgeons Consensus Guideline on Diagnosis and Management of Cystic Breast Lesions

Practice Reproductive questions on FirstPassPA

Turn this outline into retention. 3,500+ board-style questions with an AI tutor that explains every answer — free to start, no card required.

Start studying free → Browse all 514 diagnoses

Educational use only. This outline is a study aid for PA students and is not medical advice or a substitute for clinical judgment. FirstPassPA is an independent study tool and is not affiliated with, endorsed by, or sponsored by NCCPA. PANCE® and PANRE® are registered trademarks of the National Commission on Certification of Physician Assistants.